Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 7/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065426 | 0.88 | DRD4 (0.42) | KDM4ENPC1RAB9ADRD4SLC6A12 | |
| SCHEMBL2065134 | 0.86 | GSK3B (0.46) | NPC1RAB9A | |
| SCHEMBL2066272 | 0.86 | GRM5 (0.50) | NPC1RAB9A | |
| SCHEMBL2064828 | 0.83 | GSK3B (0.50) | PREP | |
| SCHEMBL2065337 | 0.83 | SMN1; SMN2 (0.45) | KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL2066118 | 0.83 | ALDH1A1 (0.43) | RAB9AMEN1KMT2A | |
| SCHEMBL4390474 | 0.83 | ALDH1A1 (0.46) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL3375649 | 0.82 | GSK3B (0.40) | — | |
| SCHEMBL4385754 | 0.82 | HPGD (0.54) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL2067123 | 0.80 | ROCK1 (0.43) | RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148364-B2 | Substituted bicyclic pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | claimed |
| EP-1957492-B1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | claimed |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | claimed |
| EP-1957492-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | sanofi-aventis (FR) | 2008-08-20 | — | — | EP | claimed |
| EP-1790649-A1 | Substituted bicyclic pyrimidone derivatives | Sanofi-Aventis (FR) | 2007-05-30 | — | — | EP | claimed |
| WO-2007057790-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-05-24 | — | — | WO | claimed |
| US-8148364-B2 | Substituted bicyclic pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| EP-1957492-B1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | disclosed |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1957492-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | sanofi-aventis (FR) | 2008-08-20 | — | — | EP | disclosed |
| EP-1790649-A1 | Substituted bicyclic pyrimidone derivatives | Sanofi-Aventis (FR) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007057790-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | KDM4E 2487/4885NPC1 1296/4885RAB9A 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.